SIBN - SI-BONE guides Q4 and FY22 revenue above estimates
-
SI-Bone ( NASDAQ: SIBN ) expects Q4 worldwide revenue to be in the range of $31.7M-$31.9M, representing growth of ~26% Y/Y, vs consensus of $30.05M .
-
Q4 U.S. revenue expected to be in the range of $29.8M-$29.9M, representing growth of ~28% Y/Y.
-
The company ended the quarter with a record 920 active surgeons in the U.S., representing growth of ~33% Y/Y.
-
FY22 worldwide revenue expected to be in the range of $106.1M-106.3M, representing growth of ~18% Y/Y, vs consensus of $104.56M .
- FY22 U.S. revenue expected to be in the range of $98.6M-$98.7M, representing growth of ~19% Y/Y.
- Cash and marketable securities are expected to be ~$96M as of December 31, 2022.
For further details see:
SI-BONE guides Q4 and FY22 revenue above estimates